Skip to main
ARAY

Accuray (ARAY) Stock Forecast & Price Target

Accuray (ARAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Accuray is expected to improve operating profitability by ~$25M annually through its transformation plan and has already recognized $10M in cost and margin improvements. Despite recent challenges, the company's technology, including its CyberKnife and TomoTherapy platforms, positions it as a leader in the radiation oncology space. However, the company's results have been impacted by geopolitical uncertainty, macroeconomic headwinds, and other factors which has led analysts to adopt a neutral stance.

Bears say

Accuray is a radiation oncology company, with its main system being CyberKnife. Unfortunately, the company has been impacted by geopolitical tensions and uncertainties, and has missed expectations on both adj. EBITDA and cost-cutting efforts. Though the company has a transformation plan underway, the lack of progress on commercial execution and profitability metrics, along with declining revenue, make it a risky investment at this time.

Accuray (ARAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Accuray (ARAY) Forecast

Analysts have given Accuray (ARAY) a Buy based on their latest research and market trends.

According to 2 analysts, Accuray (ARAY) has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Accuray (ARAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.